<DOC>
	<DOCNO>NCT01387958</DOCNO>
	<brief_summary>This proof concept study , design look safety antiviral activity LCQ908 hepatitis C infect patient .</brief_summary>
	<brief_title>A Two Week Dosing Study Determine Safety Antiviral Activity LCQ908 Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Written inform consent . Male female subject 18 65 year age hepatitis C infection ( genotype 1 , 2 3 ) . No prior therapy inadequate response therapy hepatitis C. Weight least 50 kg body mass index ( BMI ) within 18 35 kg/m2 . Use investigational drug within least 30 day enrollment Women childbearing potential . Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Chronically infect</keyword>
	<keyword>treatment naive</keyword>
	<keyword>non responder prior therapy</keyword>
</DOC>